Furthermore, the addition of Akt inhibitor MK2206 maintained CAR T cells in a less differentiated state in vitro without impairing their activation, leading to significantly longer CAR T cell persistence and enhanced anti-tumor activity in vivo (276). The gene discussed is AKT1; the disease is neoplasm.